AbbVie Inc.’s stock rose 5% early Friday to lead S&P 500 gainers premarket, after the drug company beat fourth-quarter ...

The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

AbbVie is a Dividend King that's quickly moving past reliance on Humira. Enbridge shouldn't be affected by potential Canadian ...

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking ...

AbbVie (NYSE:ABBV) is ticking up; according to a new Samsung Bioepis report, Humira's U.S. market share stays above 70% even with increasing biosimilar competition. Humira still dominated 96% of ...

AbbVie is a resurging Dividend King. Amgen's recent clinical setback makes its stock available at a discount. Gilead Sciences is a steady dividend payer with a growing payout. For a while, though, ...

Says therapeutic portfolio ‘demonstrating very strong momentum’ into 2025. Says making “significant progress” in R&D efforts. Invest with ...

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic drugmaker Samsung Bioepis said in a new report on Thursday as the ...

AbbVie holds a strong portfolio of marketed and pipeline drugs. While the increasing competition to the company's key drug Humira should slow the growth for the company in the near term ...

"We are entering 2025 with significant momentum and expect net revenues to exceed their previous peak in just the second full year following the U.S. Humira loss of exclusivity," Chief Executive ...